Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
Using a heart failure animal model, Saillant found out that the new treatment (ST02) restored heart function in failing hearts after four weeks of treatment. Treated hearts reversed to normal geometry with a significant reduction in scar tissue (fibrosis).
Lead Product(s): ST02
Therapeutic Area: Cardiology/Vascular Diseases Product Name: ST02
Highest Development Status: PreclinicalProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 04, 2020
Details:
Saillant Therapeutics has discovered an innovative groundbreaking generic virus-inhibiting treatment platform based on activation of a cellular master regulator.
Lead Product(s): Undisclosed
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: PreclinicalProduct Type: Undisclosed
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 14, 2020